Share on StockTwits

Hyperion Therapeutics (NASDAQ:HPTX) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday. The firm currently has a $25.00 price target on the stock. Zacks‘s target price points to a potential upside of 6.66% from the company’s current price.

Hyperion Therapeutics (NASDAQ:HPTX) traded down 0.04% on Tuesday, hitting $23.43. The stock had a trading volume of 97,314 shares. Hyperion Therapeutics has a 1-year low of $18.97 and a 1-year high of $32.98. The stock has a 50-day moving average of $24.35 and a 200-day moving average of $26.09. The company has a market cap of $476.4 million and a price-to-earnings ratio of 26.04.

Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Thursday, August 7th. The company reported $0.81 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.03) by $0.84. The company had revenue of $37.10 million for the quarter, compared to the consensus estimate of $22.00 million. During the same quarter last year, the company posted $1.17 earnings per share. Hyperion Therapeutics’s revenue was up 408.2% compared to the same quarter last year. Analysts expect that Hyperion Therapeutics will post $-0.14 EPS for the current fiscal year.

Separately, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Hyperion Therapeutics in a research note on Friday. They now have a $37.00 price target on the stock, down previously from $39.00. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $35.17.

Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.